IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate -mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research[1].
Product Specifications
UNSPSC
12352100
Target
CD73; IFNAR; Interleukin Related; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology
References & Citations
[1]Zhou Y, et al. Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. Int J Biol Macromol. 2023 Feb 28;229:158-167.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
IL-2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K2112605 3x 1.0 µg
SEC14L5 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details 